Jason Lettmann, Lightstone Ventures

Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

Neu­ro­science is hav­ing a mo­ment right now, and one VC firm strad­dling the line be­tween biotech and medtech is look­ing to cap­i­tal­ize on the field’s rapid growth.

Light­stone Ven­tures has raised $375 mil­lion for its third ven­ture fund with an eye on ex­pand­ing its fo­cus in CNS dis­ease, the firm said Tues­day.

The newest raise brings Light­stone’s to­tal to more than $850 mil­lion since the firm was found­ed back in 2012. So far, that trea­sure chest has led to in­vest­ments in around 30 com­pa­nies split across the biotech and medtech spaces. With its third and largest fund, Light­stone is ex­pect­ing much the same as be­fore — most­ly in­vest­ments in seed-stage to Se­ries A com­pa­nies with an eye on “break­throughs” in pa­tient care, gen­er­al part­ner Ja­son Lettmann told End­points News.

What is new, Lettmann said, is a broad­er fo­cus on CNS star­tups, which con­tin­ues Light­stone’s piv­ot in­to that space dat­ing back to the firm’s sec­ond fund. But the team is al­so keep­ing the door open in oth­er ther­a­peu­tic ar­eas.

“Look­ing for­ward, we are plan­ning to spend a lot of time (in CNS),” Lettman said. “We re­al­ly do be­lieve CNS is the next fron­tier. We’re go­ing to try to spend more time in the un­der­ap­pre­ci­at­ed ar­eas, whether that’s au­toim­mune, im­munol­o­gy, etc. That’s where we’ll prob­a­bly look.”

In terms of tar­get­ed deal size or how many com­pa­nies are on the hit list, Lettman was mum, say­ing Light­stone will look at deals of rough­ly the same size and de­vel­op­ment stage, this time with more cap­i­tal flex­i­bil­i­ty, and re­main open to “op­por­tunis­tic” late-stage fly­ers.

In ear­ly-stage in­vest­ment, one of the biggest de­bates among VCs is the prod­uct-vs-plat­form par­a­digm, and Lettmann had some thoughts on ex­act­ly how his firm thinks about that di­vide. Light­stone tar­gets what it calls plat­form plays in both the biotech and medtech space but asks com­pa­nies to quick­ly nar­row the fo­cus around a sin­gle or clutch of prod­ucts.

“We don’t in­vest in plat­forms just for the sake of a plat­form,” Lettman said. “I think one of the things we’re most proud of is how many of our com­pa­nies have ul­ti­mate­ly de­vel­oped ther­a­pies that have been ap­proved in pa­tients. So I think our strat­e­gy is to find things where there are mul­ti­ple shots on goal but re­al­ly quick­ly piv­ot to a prod­uct fo­cus.”

Get­ting in ear­ly at the seed stage for com­pa­nies af­fords Light­stone a chance to help en­tre­pre­neurs shape their com­pa­ny’s tra­jec­to­ry mov­ing in­to the fu­ture. For Lettmann, the ide­al part­ner en­tre­pre­neurs are “op­er­a­tors” with ex­pe­ri­ence in the space and with star­tups, but the firm still takes a hands-on ap­proach when deal­ing with com­pa­nies.

“I think one of the ad­van­tages of a fund of our size is the abil­i­ty to re­al­ly fo­cus and spend the time to launch those com­pa­nies,” he said. “We do re­al­ly try to roll up our sleeves.”

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Dipal Doshi, Entrada Therapeutics CEO

Ver­tex just found the next big ‘trans­for­ma­tive’ thing for the pipeline — at a biotech just down the street

Back in the summer of 2019, when I was covering Vertex’s executive chairman Jeff Leiden’s plans for the pipeline, I picked up on a distinct focus on myotonic dystrophy Type I, or DM1 — one of what Leiden called “two diseases (with DMD) we’re interested in and we continue to look for those assets.”

Today, Leiden’s successor at the helm of Vertex, CEO Reshma Kewalramani, is plunking down $250 million in cash to go the extra mile on DM1. The lion’s share of that is for the upfront, with a small reserve for equity in a deal that lines Vertex up with a neighbor in Seaport that has been rather quietly going at both of Vertex’s early disease targets with preclinical assets.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Christian Itin, Autolus CEO (UKBIO19)

Au­to­lus tips its hand, bags $220M as CAR-T show­down with Gilead looms

The first batch of pivotal data on Autolus Therapeutics’ CAR-T is in, and execs are ready to plot a path to market.

With an overall remission rate of 70% at the interim analysis featuring 50 patients, the results set the stage for a BLA filing by the end of 2023, said CEO Christian Itin.

Perhaps more importantly — given that Autolus’ drug, obe-cel, is going after an indication that Gilead’s Tecartus is already approved for — the biotech highlighted “encouraging safety data” in the trial, with a low percentage of patients experiencing severe immune responses.

WIB22: Am­ber Salz­man had few op­tions when her son was di­ag­nosed with a rare ge­net­ic dis­ease. So she cre­at­ed a bet­ter one

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

Amber Salzman’s life changed on a cold, damp day in Paris over tiny plastic cups of lukewarm tea.

She was meeting with Patrick Aubourg, a French neurologist studying adrenoleukodystrophy, or ALD, a rare genetic condition that causes rapid neurological decline in young boys. It’s a sinister disease that often leads to disability or death within just a few years. Salzman’s nephew was diagnosed at just 6 or 7 years old, and died at the age of 12.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

Ahead of ad­comm, FDA rais­es un­cer­tain­ties on ben­e­fit-risk pro­file of Cy­to­ki­net­ic­s' po­ten­tial heart drug

The FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics’ potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.

The drug, known as omecamtiv mecarbil and in development for more than 15 years, has seen mixed results, with a first Phase III readout from November 2020 hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as key to breaking into the market.

Ab­b­Vie slapped with age dis­crim­i­na­tion law­suit, fol­low­ing oth­er phar­mas

Add AbbVie to the list of pharma companies currently facing age discrimination allegations.

Pennsylvania resident Thomas Hesch filed suit against AbbVie on Wednesday, accusing the company of passing him over for promotions in favor of younger candidates.

Despite 30 years of pharma experience, “Hesch has consistently seen younger, less qualified employees promoted over him,” the complaint states.

Rami Elghandour, Arcellx CEO

Up­dat­ed: Gilead, Ar­cel­lx team up on an­ti-BC­MA CAR-T as biotech touts a 100% re­sponse rate at #ASH22

Gilead and Kite are plunking down big cash to get into the anti-BCMA CAR-T game.

The pair will shell out $225 million in cash upfront and $100 million in equity to Arcellx, Kite announced Friday morning, to develop the biotech’s lead CAR-T program together. Kite will handle commercialization and co-development with Arcellx, and profits in the US will be split 50-50.

Concurrent with the deal, Arcellx revealed its latest cut of data for the program known as CART-ddBCMA, ahead of a full presentation at this weekend’s ASH conference — a 100% response rate among patients getting the therapy. Investors jumped at the dual announcements, sending Arcellx shares $ACLX up more than 25% in Friday’s morning session.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

WIB22: Lead­ing NK cell re­searcher re­flects on roots in Iran, the UK and Texas

This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.

In a small but widely-cited 11-person study published in NEJM in 2020, seven patients saw signs of their cancer completely go away after getting a new therapy made from natural killer cells. The study was one of the earliest to provide clinical proof that the experimental treatment method had promise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.

Philip Astley-Sparke, Replimune CEO

Replimune looks to rope in $225M on the back of melanoma da­ta

The Massachusetts-based, oncolytic virus biotech Replimune is feeling bullish now that it has lifted the cover on data for its lead product.

Replimune said Thursday it looks to nab about $225 million from a public offering after giving a snapshot of some initial data from its IGNYTE clinical study earlier this week. The trial is investigating RP1 in combination with Opdivo, for patients with melanoma and who did not have a response when being treated with a PD-1.